Thomas Powles
Barts Cancer Center, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK
Thomas Powles, MD, MRCP, MBBS, is a Professor of Genitourinary Oncology and Director of Barts Centre in London, UK. He trained in medical oncology at Imperial College London, completed post-graduate training in oncology in 2005, and received an MD from the University of London in 2006, with a thesis on mechanisms of resistance to therapy in urological cancers.
Professor Powles is the lead for solid tumor research at Barts Cancer Institute, and the PI of a spectrum of clinical studies from Phase I-III, including biomarker, novel targeted and immune therapies studies.
He has written over 300 peer-reviewed publications including work in all the major journals. Professor Powles participates in and leads a number guidelines committees.
Disclosures:
- Consultancy/honorarium: AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono (EMD in US), Astellas, Johnson & Johnson, Eisai, Roche
- Grant/funding to institution: AstraZeneca, Roche, BMS, Exelixis, Ipsen Merck MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono (EMD in US), Astellas , Johnson & Johnson , Eisai
- Travel/accommodation: Roche, Pfizer, MSD, AstraZeneca, Ipsen